

# Andrew J Pollard

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1130584/andrew-j-pollard-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

349  
papers

19,730  
citations

66  
h-index

133  
g-index

387  
ext. papers

28,982  
ext. citations

11.9  
avg, IF

7.17  
L-index

#	Paper	IF	Citations
349	Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial.. <i>MSphere</i> , <b>2022</b> , e0067421	5	0
348	Innovative vaccine approaches-a Keystone Symposia report.. <i>Annals of the New York Academy of Sciences</i> , <b>2022</b> ,	6.5	1
347	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.. <i>Cell</i> , <b>2022</b> ,	56.2	154
346	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.. <i>Lancet, The</i> , <b>2022</b> ,	40	46
345	International links between <i>Streptococcus pneumoniae</i> vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease.. <i>Vaccine</i> , <b>2022</b> , 40, 1054-1054 <sup>1</sup>	4.1	0
344	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.. <i>Cell</i> , <b>2022</b> , 185, 916-938, 958	35.8	17
343	National rates and disparities in childhood vaccination and vaccine-preventable disease during the COVID-19 pandemic: English sentinel network retrospective database study.. <i>Archives of Disease in Childhood</i> , <b>2022</b> ,	2.2	2
342	CMV-associated T cell and NK cell terminal differentiation does not impact immunogenicity of ChAdOx1 vaccination.. <i>JCI Insight</i> , <b>2022</b> ,	9.9	4
341	Divergent trajectories of antiviral memory after SARS-CoV-2 infection.. <i>Nature Communications</i> , <b>2022</b> , 13, 1251	17.4	1
340	Decoupling of omicron variant infections and severe COVID-19.. <i>Lancet, The</i> , <b>2022</b> ,	40	4
339	Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR.. <i>Journal of Clinical Microbiology</i> , <b>2022</b> , e0228321	9.7	0
338	Genetic Susceptibility to Enteric Fever in Experimentally Challenged Human Volunteers.. <i>Infection and Immunity</i> , <b>2022</b> , e0038921	3.7	1
337	Future reporting of vaccine uptake needs to include any change in ethnic or socioeconomic disparities.. <i>BMJ, The</i> , <b>2022</b> , 377, o1233	5.9	
336	Viral vector vaccines. <i>Current Opinion in Immunology</i> , <b>2022</b> , 77, 102210	7.8	2
335	Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. <b>2021</b> ,		25
334	Potential global impacts of alternative dosing regimen and rollout options for the ChAdOx1 nCoV-19 vaccine. <i>Nature Communications</i> , <b>2021</b> , 12, 6370	17.4	1
333	Understanding the bonding mechanisms of organic molecules deposited on graphene for biosensing applications. <i>Journal of Chemical Physics</i> , <b>2021</b> , 155, 174703	3.9	0

332	Should children be vaccinated against COVID-19?. <i>Archives of Disease in Childhood</i> , <b>2021</b> ,	2.2	15
331	TIPICO XI: report of the first series and podcast on infectious diseases and vaccines (aTIPICO). <i>Human Vaccines and Immunotherapeutics</i> , <b>2021</b> , 1-29	4.4	
330	Burden of enteric fever at three urban sites in Africa and Asia: a multicentre population-based study. <i>The Lancet Global Health</i> , <b>2021</b> , 9, e1688-e1696	13.6	3
329	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , <b>2021</b> , 184, 5699-5714.e11	56.2	64
328	Vaccine nationalism and internationalism: perspectives of COVID-19 vaccine trial participants in the United Kingdom. <i>BMJ Global Health</i> , <b>2021</b> , 6,	6.6	3
327	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. <i>Nature Communications</i> , <b>2021</b> , 12, 5861	17.4	11
326	Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination. <i>Lancet, The</i> , <b>2021</b> , 398, 1683-1684	4.0	13
325	Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial. <i>Clinical and Translational Science</i> , <b>2021</b> ,	4.9	1
324	Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen. <i>BMC Genomics</i> , <b>2021</b> , 22, 777	4.5	1
323	Typhi Vi capsule prime-boost vaccination induces convergent and functional antibody responses. <i>Science Immunology</i> , <b>2021</b> , 6, eabj1181	2.8	0
322	Vi-specific serological correlates of protection for typhoid fever. <i>Journal of Experimental Medicine</i> , <b>2021</b> , 218,	16.6	11
321	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , <b>2021</b> , 396, 1979-1993	4.0	646
320	RNA2HLA: HLA-based quality control of RNA-seq datasets. <i>Briefings in Bioinformatics</i> , <b>2021</b> , 22,	13.4	1
319	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , <b>2021</b> , 397, 881-891	4.0	495
318	Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. <i>Lancet, The</i> , <b>2021</b> , 397, 1023-1034	4.0	367
317	Host restriction, pathogenesis and chronic carriage of typhoidal Salmonella. <i>FEMS Microbiology Reviews</i> , <b>2021</b> , 45,	15.1	1
316	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. <i>Nature Communications</i> , <b>2021</b> , 12, 2055	17.4	37
315	The antigenic anatomy of SARS-CoV-2 receptor binding domain. <i>Cell</i> , <b>2021</b> , 184, 2183-2200.e22	56.2	145

314	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. <i>Cell</i> , <b>2021</b> , 184, 2348-2361.e6	56.2	549
313	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , <b>2021</b> , 397, 1351-1362	40	316
312	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. <i>Cell</i> , <b>2021</b> , 184, 2201-2211.e7	56.2	269
311	Antiviral surfaces and coatings and their mechanisms of action. <i>Communications Materials</i> , <b>2021</b> , 2,	6	45
310	Antibody evasion by the P.1 strain of SARS-CoV-2. <i>Cell</i> , <b>2021</b> , 184, 2939-2954.e9	56.2	281
309	Gas Cluster Ion Beam Cleaning of CVD-Grown Graphene for Use in Electronic Device Fabrication. <i>ACS Applied Nano Materials</i> , <b>2021</b> , 4, 5187-5197	5.6	1
308	Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey results. <i>Lancet Infectious Diseases, The</i> , <b>2021</b> , 21, 677-687	25.5	4
307	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1885-1898	59.2	639
306	Systems Immunology: Revealing Influenza Immunological Imprint. <i>Viruses</i> , <b>2021</b> , 13,	6.2	2
305	ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - Authors' reply. <i>Lancet, The</i> , <b>2021</b> , 397, 2248	40	3
304	T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire <b>2021</b> ,		7
303	A Typhi Controlled Human Infection Study for Assessing Correlation between Bactericidal Antibodies and Protection against Infection Induced by Typhoid Vaccination. <i>Microorganisms</i> , <b>2021</b> , 9,	4.9	3
302	Should we delay covid-19 vaccination in children?. <i>BMJ, The</i> , <b>2021</b> , 374, n1687	5.9	5
301	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , <b>2021</b> , 397, 99-111	40	2110
300	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , <b>2021</b> , 27, 279-288	50.5	135
299	A guide to vaccinology: from basic principles to new developments. <i>Nature Reviews Immunology</i> , <b>2021</b> , 21, 83-100	36.5	226
298	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , <b>2021</b> , 27, 270-278	50.5	225
297	What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. <i>Lancet Infectious Diseases, The</i> , <b>2021</b> , 21, e26-e35	25.5	251

296	Rapid monitoring of graphene exfoliation using NMR proton relaxation. <i>Nanoscale</i> , <b>2021</b> , 13, 14518-14524	7.7	0
295	Using nuclear magnetic resonance proton relaxation to probe the surface chemistry of carbon 2D materials. <i>Nanoscale</i> , <b>2021</b> , 13, 6389-6393	7.7	2
294	MAIT cell activation augments adenovirus vector vaccine immunogenicity. <i>Science</i> , <b>2021</b> , 371, 521-526	33.3	27
293	Changes in epigenetic profiles throughout early childhood and their relationship to the response to pneumococcal vaccination. <i>Clinical Epigenetics</i> , <b>2021</b> , 13, 29	7.7	0
292	Unlocking thermogravimetric analysis (TGA) in the fight against fake graphene materials. <i>Carbon</i> , <b>2021</b> , 179, 505-513	10.4	17
291	Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus. <i>Nature Communications</i> , <b>2021</b> , 12, 5125	17.4	3
290	Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. <i>Lancet, The</i> , <b>2021</b> , 398, 675-684	40	13
289	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV, the</i> , <b>2021</b> , 8, e474-e485	7.8	62
288	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , <b>2021</b> , 184, 4220-4236.e13	42.6	16
287	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. <i>Nature Communications</i> , <b>2021</b> , 12, 5061	17.4	42
286	Association of Antibody-Dependent Neutrophil Phagocytosis With Distinct Antibody Glycosylation Profiles Following Typhoid Vaccination. <i>Frontiers in Tropical Diseases</i> , <b>2021</b> , 2,		1
285	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. <i>Lancet HIV, the</i> , <b>2021</b> , 8, e568-e580	7.8	38
284	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , <b>2021</b> , 13, eabj7211	17.5	20
283	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , <b>2021</b> , 27, 2032-2040	50.5	232
282	Recent advances in lipopolysaccharide-based glycoconjugate vaccines. <i>Expert Review of Vaccines</i> , <b>2021</b> , 1-24	5.2	1
281	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , <b>2021</b> , 398, 981-990	40	68
280	SIMON: Open-Source Knowledge Discovery Platform. <i>Patterns</i> , <b>2021</b> , 2, 100178	5.1	6
279	ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply. <i>Lancet, The</i> , <b>2020</b> , 396, 1486-1487	40	4

278	Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa143	1	1
277	Priorities for developing respiratory syncytial virus vaccines in different target populations. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	12
276	Raman Fingerprints of Graphene Produced by Anodic Electrochemical Exfoliation. <i>Nano Letters</i> , <b>2020</b> , 20, 3411-3419	11.5	25
275	Gas physisorption measurements as a quality control tool for the properties of graphene/graphite powders. <i>Carbon</i> , <b>2020</b> , 167, 585-595	10.4	9
274	Determining the Level and Location of Functional Groups on Few-Layer Graphene and Their Effect on the Mechanical Properties of Nanocomposites. <i>ACS Applied Materials &amp; Interfaces</i> , <b>2020</b> , 12, 13481-13493	9.5	19
273	The science of vaccine safety: Summary of meeting at Wellcome Trust. <i>Vaccine</i> , <b>2020</b> , 38, 1869-1880	4.1	10
272	Progress in the overall understanding of typhoid fever: implications for vaccine development. <i>Expert Review of Vaccines</i> , <b>2020</b> , 19, 367-382	5.2	1
271	Two centuries of immunisation in the UK (part 1). <i>Archives of Disease in Childhood</i> , <b>2020</b> , 105, 115-121	2.2	1
270	Ebola virus glycoprotein stimulates IL-18-dependent natural killer cell responses. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 3936-3946	15.9	5
269	Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. <i>Wellcome Open Research</i> , <b>2020</b> , 5, 139	4.8	120
268	Homologous and heterologous re-challenge with Salmonella Typhi and Salmonella Paratyphi A in a randomised controlled human infection model. <i>PLoS Neglected Tropical Diseases</i> , <b>2020</b> , 14, e0008783	4.8	3
267	Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine. <i>Molecular Systems Biology</i> , <b>2020</b> , 16, e9888	12.2	2
266	Electronic data capture for large scale typhoid surveillance, household contact tracing, and health utilisation survey: Strategic Typhoid Alliance across Africa and Asia. <i>Wellcome Open Research</i> , <b>2020</b> , 5, 66	4.8	3
265	Electronic data capture for large scale typhoid surveillance, household contact tracing, and health utilisation survey: Strategic Typhoid Alliance across Africa and Asia. <i>Wellcome Open Research</i> , <b>2020</b> , 5, 66	4.8	3
264	Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. <i>Vaccine</i> , <b>2020</b> , 38, 4783-4791	4.1	78
263	Visualizing variation within Global Pneumococcal Sequence Clusters (GPSCs) and country population snapshots to contextualize pneumococcal isolates. <i>Microbial Genomics</i> , <b>2020</b> , 6,	4.4	13
262	Two centuries of immunisation in the UK (part II). <i>Archives of Disease in Childhood</i> , <b>2020</b> , 105, 216-222	2.2	3
261	Integrated Wafer Scale Growth of Single Crystal Metal Films and High Quality Graphene. <i>ACS Nano</i> , <b>2020</b> , 14, 13593-13601	16.7	11

260	Why the elderly appear to be more severely affected by COVID-19: The potential role of immunosenescence and CMV. <i>Reviews in Medical Virology</i> , <b>2020</b> , 30, e2144	11.7	44
259	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , <b>2020</b> , 396, 467-478	4.0	1274
258	Notice of addendum to Article reporting Oxford trial of ChAdOx1 nCoV-19 vaccine. <i>Lancet, The</i> , <b>2020</b> , 396, e89	4.0	2
257	Nanoscale characterization of plasma functionalized graphitic flakes using tip-enhanced Raman spectroscopy. <i>Journal of Chemical Physics</i> , <b>2020</b> , 153, 184708	3.9	7
256	Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 574057	8.4	3
255	Mechanical properties of the hollow-wall graphene gyroid lattice. <i>Acta Materialia</i> , <b>2020</b> , 201, 254-265	8.4	6
254	Human Typhi exposure generates differential multifunctional cross-reactive T-cell memory responses against Paratyphi and invasive nontyphoidal. <i>Clinical and Translational Immunology</i> , <b>2020</b> , 9, e1178	6.8	0
253	Payment in challenge studies: ethics, attitudes and a new payment for risk model. <i>Journal of Medical Ethics</i> , <b>2020</b> , 46, 815-826	2.5	15
252	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. <i>Lancet Infectious Diseases, The</i> , <b>2020</b> , 20, 1390-1400	25.5	212
251	What time interval is needed between the administration of live attenuated vaccines?. <i>Archives of Disease in Childhood</i> , <b>2020</b> , 105, 1232-1235	2.2	
250	Bone and joint infections in Oxford: a 10-year retrospective review. <i>Archives of Disease in Childhood</i> , <b>2020</b> , 105, 515-516	2.2	
249	Common Genetic Variations Associated with the Persistence of Immunity following Childhood Immunization. <i>Cell Reports</i> , <b>2019</b> , 27, 3241-3253.e4	10.6	16
248	The Role and Control of Residual Bulk Oxygen in the Catalytic Growth of 2D Materials. <i>Journal of Physical Chemistry C</i> , <b>2019</b> , 123, 16257-16267	3.8	14
247	The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations. <i>Vaccine</i> , <b>2019</b> , 37, 3190-3198	4.1	17
246	Identification of regulatory variants associated with genetic susceptibility to meningococcal disease. <i>Scientific Reports</i> , <b>2019</b> , 9, 6966	4.9	3
245	Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study. <i>Vaccine</i> , <b>2019</b> , 37, 3485-3494	4.1	15
244	Nanoscale chemical imaging using tip-enhanced Raman spectroscopy. <i>Nature Protocols</i> , <b>2019</b> , 14, 1169-1188	11.8	50
243	The effect of a single 4CMenB vaccine booster in young people more than ten years after infant immunisation: protocol of an exploratory immunogenicity study. <i>Trials</i> , <b>2019</b> , 20, 455	2.8	2

242	Reactive intercalation and oxidation at the buried graphene-germanium interface. <i>APL Materials</i> , <b>2019</b> , 7, 071107	5.7	10
241	Investigation of the role of typhoid toxin in acute typhoid fever in a human challenge model. <i>Nature Medicine</i> , <b>2019</b> , 25, 1082-1088	50.5	14
240	Comparative transcriptomics between species attributes reactogenicity pathways induced by the capsular group B meningococcal vaccine, 4CMenB, to the membrane-bound endotoxin of its outer membrane vesicle component. <i>Scientific Reports</i> , <b>2019</b> , 9, 13797	4.9	7
239	UKMenCar4: A cross-sectional survey of asymptomatic meningococcal carriage amongst UK adolescents at a period of low invasive meningococcal disease incidence. <i>Wellcome Open Research</i> , <b>2019</b> , 4, 118	4.8	3
238	Diagnostic host gene signature for distinguishing enteric fever from other febrile diseases. <i>EMBO Molecular Medicine</i> , <b>2019</b> , 11, e10431	12	7
237	UKMenCar4: A cross-sectional survey of asymptomatic meningococcal carriage amongst UK adolescents at a period of low invasive meningococcal disease incidence. <i>Wellcome Open Research</i> , <b>2019</b> , 4, 118	4.8	2
236	Tonsillectomy for periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA). <i>The Cochrane Library</i> , <b>2019</b> , 12, CD008669	5.2	9
235	IgA and IgG1 Specific to Vi Polysaccharide of Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2582	8.4	16
234	Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 2209-2218	59.2	82
233	Treatment responses to Azithromycin and Ciprofloxacin in uncomplicated Salmonella Typhi infection: A comparison of Clinical and Microbiological Data from a Controlled Human Infection Model. <i>PLoS Neglected Tropical Diseases</i> , <b>2019</b> , 13, e0007955	4.8	10
232	The Impact of Vaccination and Prior Exposure on Stool Shedding of Salmonella Typhi and Salmonella Paratyphi in 6 Controlled Human Infection Studies. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 1265-1273	11.6	16
231	Human challenge trials in vaccine development, Rockville, MD, USA, September 28-30, 2017. <i>Biologicals</i> , <b>2019</b> , 61, 85-94	1.8	19
230	Management of suspected paediatric meningitis: a multicentre prospective cohort study. <i>Archives of Disease in Childhood</i> , <b>2018</b> , 103, 1114-1118	2.2	4
229	<i>Neisseria meningitidis</i> <b>2018</b> , 747-759.e5		1
228	MAIT cell clonal expansion and TCR repertoire shaping in human volunteers challenged with Salmonella ParatyphiA. <i>Nature Communications</i> , <b>2018</b> , 9, 253	17.4	66
227	Graphene: civil engineering applications start to come to fruition. <i>Proceedings of the Institution of Civil Engineers: Civil Engineering</i> , <b>2018</b> , 171, 15-15	0.4	
226	Change in viral bronchiolitis management in primary care in the UK after the publication of NICE guideline. <i>Thorax</i> , <b>2018</b> ,	7.3	9
225	Nanoscale chemical imaging of solid-liquid interfaces using tip-enhanced Raman spectroscopy. <i>Nanoscale</i> , <b>2018</b> , 10, 1815-1824	7.7	51



224	The Family Context of Assent: Comparison of Child and Parent Perspectives on Familial Decision-Making. <i>Children and Society</i> , <b>2018</b> , 32, 266-278	1.4	
223	Viral bronchiolitis management in hospitals in the UK. <i>Journal of Clinical Virology</i> , <b>2018</b> , 104, 29-33	14.5	7
222	A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. <i>Vaccine</i> , <b>2018</b> , 36, 2300-2306	4.1	7
221	Incomplete penetrance for isolated congenital asplenia in humans with mutations in translated and untranslated exons. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, E8007-E8016	11.5	24
220	Change in viral bronchiolitis management in hospitals in the UK after the publication of NICE guideline. <i>Journal of Clinical Virology</i> , <b>2018</b> , 105, 84-87	14.5	5
219	Clonal analysis of Salmonella-specific effector T cells reveals serovar-specific and cross-reactive T cell responses. <i>Nature Immunology</i> , <b>2018</b> , 19, 742-754	19.1	16
218	Physicochemical characterisation of reduced graphene oxide for conductive thin films.. <i>RSC Advances</i> , <b>2018</b> , 8, 37540-37549	3.7	10
217	Differences in Immunization Site Pain in Toddlers Vaccinated With Either the 10- or the 13-Valent Pneumococcal Conjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , <b>2018</b> , 37, e103-e106	3.4	1
216	Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci. <i>PLoS Pathogens</i> , <b>2018</b> , 14, e1007438	7.6	37
215	Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection. <i>Vaccine</i> , <b>2018</b> , 36, 6988-6994	4.1	
214	Typhoid and paratyphoid fever: a call to action. <i>Current Opinion in Infectious Diseases</i> , <b>2018</b> , 31, 440-448	5.4	33
213	Laboratory and molecular surveillance of paediatric typhoidal Salmonella in Nepal: Antimicrobial resistance and implications for vaccine policy. <i>PLoS Neglected Tropical Diseases</i> , <b>2018</b> , 12, e0006408	4.8	47
212	Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines <b>2018</b> , 619-643.e11		7
211	Meningococcal Capsular Group B Vaccines <b>2018</b> , 644-662.e6		6
210	High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine. <i>Genome Medicine</i> , <b>2017</b> , 9, 11	14.4	10
209	Structural, chemical and electrical characterisation of conductive graphene-polymer composite films. <i>Applied Surface Science</i> , <b>2017</b> , 403, 403-412	6.7	23
208	Blood culture-PCR to optimise typhoid fever diagnosis after controlled human infection identifies frequent asymptomatic cases and evidence of primary bacteraemia. <i>Journal of Infection</i> , <b>2017</b> , 74, 358-366	18.9	15
207	Production of few-layer graphene by microfluidization. <i>Materials Research Express</i> , <b>2017</b> , 4, 025604	1.7	31

206	Memory B cell response to a PCV-13 booster in 3.5year old children primed with either PCV-7 or PCV-13. <i>Vaccine</i> , <b>2017</b> , 35, 2701-2708	4.1	6
205	Non-specific effects of vaccines: plausible and potentially important, but implications uncertain. <i>Archives of Disease in Childhood</i> , <b>2017</b> , 102, 1077-1081	2.2	77
204	The Influence of Maternally Derived Antibody and Infant Age at Vaccination on Infant Vaccine Responses : An Individual Participant Meta-analysis. <i>JAMA Pediatrics</i> , <b>2017</b> , 171, 637-646	8.3	257
203	An evaluation of purified Salmonella Typhi protein antigens for the serological diagnosis of acute typhoid fever. <i>Journal of Infection</i> , <b>2017</b> , 75, 104-114	18.9	14
202	Prevalence and decay of maternal pneumococcal and meningococcal antibodies: A meta-analysis of type-specific decay rates. <i>Vaccine</i> , <b>2017</b> , 35, 5850-5857	4.1	15
201	Terminology: the first step towards international standardisation of graphene and related 2D materials. <i>Journal of Materials Science</i> , <b>2017</b> , 52, 13685-13688	4.3	7
200	Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. <i>Lancet, The</i> , <b>2017</b> , 390, 2472-2480	40	167
199	Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules. <i>Cmaj</i> , <b>2017</b> , 189, E1276-E1285	3.5	10
198	Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine. <i>PLoS ONE</i> , <b>2017</b> , 12, e0183427	3.7	6
197	Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge Model. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 64, 1066-1073	11.6	34
196	Investigating Systemic Immunity to Typhoid and Paratyphoid Fever: Characterising the Response to Re-challenge in a Controlled Human Infection Model. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, S227-S228 <sup>†</sup>		4
195	Typhi Bactericidal Antibodies Reduce Disease Severity but Do Not Protect against Typhoid Fever in a Controlled Human Infection Model. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1916	8.4	14
194	Preface. <i>Journal of Infection</i> , <b>2017</b> , 74 Suppl 1, S1	18.9	
193	Benchmarking of Viral Bronchiolitis Management by General Practitioners in the United Kingdom. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , <b>2017</b> , 30, 69-73	0.8	2
192	Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. <i>Lancet Public Health, The</i> , <b>2017</b> , 2, e367-e374	22.4	44
191	The STRATAA study protocol: a programme to assess the burden of enteric fever in Bangladesh, Malawi and Nepal using prospective population census, passive surveillance, serological studies and healthcare utilisation surveys. <i>BMJ Open</i> , <b>2017</b> , 7, e016283	3	33
190	Divergent Memory B Cell Responses in a Mixed Infant Pneumococcal Conjugate Vaccine Schedule. <i>Pediatric Infectious Disease Journal</i> , <b>2017</b> , 36, e130-e135	3.4	8
189	Importance of Typhi-Responsive CD8+ T Cell Immunity in a Human Typhoid Fever Challenge Model. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 208	8.4	18

188	Challenge of Humans with Wild-type Serovar Typhi Elicits Changes in the Activation and Homing Characteristics of Mucosal-Associated Invariant T Cells. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 398	8.4	32
187	The Clinical Application of MicroRNAs in Infectious Disease. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1182	8.4	97
186	Induction of Cell Cycle and NK Cell Responses by Live-Attenuated Oral Vaccines against Typhoid Fever. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1276	8.4	8
185	AS03- and MF59-Adjuvanted Influenza Vaccines in Children. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1760	8.4	66
184	Transcriptomics in Human Challenge Models. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1839	8.4	18
183	Identification of Novel Serodiagnostic Signatures of Typhoid Fever Using a Proteome Array. <i>Frontiers in Microbiology</i> , <b>2017</b> , 8, 1794	5.7	18
182	Assessment and Translation of the Antibody-in-Lymphocyte Supernatant (ALS) Assay to Improve the Diagnosis of Enteric Fever in Two Controlled Human Infection Models and an Endemic Area of Nepal. <i>Frontiers in Microbiology</i> , <b>2017</b> , 8, 2031	5.7	4
181	Duration of intravenous antibiotic therapy for children with acute osteomyelitis or septic arthritis: a feasibility study. <i>Health Technology Assessment</i> , <b>2017</b> , 21, 1-164	4.4	11
180	Admission to hospital for bronchiolitis in England: trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma. <i>Archives of Disease in Childhood</i> , <b>2016</b> , 101, 140-6	2.2	113
179	In Situ Graphene Growth Dynamics on Polycrystalline Catalyst Foils. <i>Nano Letters</i> , <b>2016</b> , 16, 6196-6206	11.5	51
178	Diagnostic Test Accuracy of a 2-Transcript Host RNA Signature for Discriminating Bacterial vs Viral Infection in Febrile Children. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 835-45	27.4	166
177	The predicted persistence and kinetics of antibody decline 9years after pre-school booster vaccination in UK children. <i>Vaccine</i> , <b>2016</b> , 34, 4221-4228	4.1	7
176	Intussusception risk after rotavirus vaccination in England. <i>Vaccine</i> , <b>2016</b> , 34, 6114	4.1	1
175	Understanding and Controlling Cu-Catalyzed Graphene Nucleation: The Role of Impurities, Roughness, and Oxygen Scavenging. <i>Chemistry of Materials</i> , <b>2016</b> , 28, 8905-8915	9.6	109
174	Metrology for graphene and 2D materials. <i>Measurement Science and Technology</i> , <b>2016</b> , 27, 092001	2	7
173	B-cell repertoire dynamics after sequential hepatitis B vaccination and evidence for cross-reactive B-cell activation. <i>Genome Medicine</i> , <b>2016</b> , 8, 68	14.4	42
172	Developing a new justification for assent. <i>BMC Medical Ethics</i> , <b>2016</b> , 17, 2	2.9	21
171	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1635-46	59.2	232

170	Prevention of meningococcal disease through vaccination <b>2016</b> , 91-103		
169	Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 1853-8	11.5	111
168	RSV vaccine use--the missing data. <i>Expert Review of Vaccines</i> , <b>2016</b> , 15, 149-52	5.2	14
167	A quantitative review of healthcare professionals' questions to a local immunization advice service: 4299 enquiries from 3 years. <i>Journal of Public Health</i> , <b>2016</b> , 38, 578-584	3.5	0
166	Ethical Criteria for Human Challenge Studies in Infectious Diseases. <i>Public Health Ethics</i> , <b>2016</b> , 9, 92-103	1.8	61
165	Covalent Carbene Functionalization of Graphene: Toward Chemical Band-Gap Manipulation. <i>ACS Applied Materials &amp; Interfaces</i> , <b>2016</b> , 8, 4870-7	9.5	36
164	Investigation of CVD graphene topography and surface electrical properties. <i>Surface Topography: Metrology and Properties</i> , <b>2016</b> , 4, 025001	1.5	3
163	Enter B and W: two new meningococcal vaccine programmes launched. <i>Archives of Disease in Childhood</i> , <b>2016</b> , 101, 91-5	2.2	75
162	Impact of Reducing Complement Inhibitor Binding on the Immunogenicity of Native Neisseria meningitidis Outer Membrane Vesicles. <i>PLoS ONE</i> , <b>2016</b> , 11, e0148840	3.7	4
161	Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults. <i>PLoS ONE</i> , <b>2016</b> , 11, e0165384	3.7	0
160	Management of Respiratory Syncytial Virus Bronchiolitis: 2015 Survey of Members of the European Society for Paediatric Infectious Diseases. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , <b>2016</b> , 2016, 9139537	2.6	10
159	Non-specific immunological effects of selected routine childhood immunisations: systematic review. <i>BMJ, The</i> , <b>2016</b> , 355, i5225	5.9	45
158	Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. <i>PLoS Neglected Tropical Diseases</i> , <b>2016</b> , 10, e0004926	4.8	49
157	The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy. <i>Pediatric Infectious Disease Journal</i> , <b>2016</b> , 35, 787-93	3.4	13
156	Control of invasive meningococcal disease: is it achievable?. <i>International Journal of Evidence-Based Healthcare</i> , <b>2016</b> , 14, 3-14	2.6	8
155	Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy. <i>Vaccine</i> , <b>2016</b> , 34, 6350-6357	4.1	
154	Interferon-driven alterations of the host's amino acid metabolism in the pathogenesis of typhoid fever. <i>Journal of Experimental Medicine</i> , <b>2016</b> , 213, 1061-77	16.6	28
153	Salmonella Typhi-specific multifunctional CD8+ T cells play a dominant role in protection from typhoid fever in humans. <i>Journal of Translational Medicine</i> , <b>2016</b> , 14, 62	8.5	43

152	Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 1610-23	27.4	189
151	Harnessing the beneficial heterologous effects of vaccination. <i>Nature Reviews Immunology</i> , <b>2016</b> , 16, 392-400	36.5	148
150	Activation of Salmonella Typhi-specific regulatory T cells in typhoid disease in a wild-type S. Typhi challenge model. <i>PLoS Pathogens</i> , <b>2015</b> , 11, e1004914	7.6	39
149	Understanding paratyphoid infection: study protocol for the development of a human model of Salmonella enterica serovar Paratyphi A challenge in healthy adult volunteers. <i>BMJ Open</i> , <b>2015</b> , 5, e007481	3.8	16
148	Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study. <i>Vaccine</i> , <b>2015</b> , 33, 4579-85	4.1	8
147	Removal of Organic Contamination from Graphene with a Controllable Mass-Selected Argon Gas Cluster Ion Beam. <i>Journal of Physical Chemistry C</i> , <b>2015</b> , 119, 17836-17841	3.8	21
146	Design, recruitment, and microbiological considerations in human challenge studies. <i>Lancet Infectious Diseases</i> , <b>2015</b> , 15, 840-51	25.5	78
145	Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. <i>BMJ</i> , <b>2015</b> , 350, h1554	5.9	24
144	BCR repertoire sequencing: different patterns of B-cell activation after two Meningococcal vaccines. <i>Immunology and Cell Biology</i> , <b>2015</b> , 93, 885-95	5	62
143	Searching for the human genetic factors standing in the way of universally effective vaccines. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , <b>2015</b> , 370,	5.8	29
142	Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months. <i>Cmaj</i> , <b>2015</b> , 187, E215-E223	3.5	25
141	Group B meningococcal vaccine science and policy. <i>Journal of Infection</i> , <b>2015</b> , 71 Suppl 1, S15-20	18.9	5
140	Investigations of the effect of SiC growth face on graphene thickness uniformity and electronic properties. <i>Surface Topography: Metrology and Properties</i> , <b>2015</b> , 3, 015001	1.5	5
139	Probing individual point defects in graphene via near-field Raman scattering. <i>Nanoscale</i> , <b>2015</b> , 7, 19413-8.7	8.7	32
138	Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. <i>Science Translational Medicine</i> , <b>2015</b> , 7, 300ra126	17.5	93
137	Needle-Free Dermal Delivery of a Diphtheria Toxin CRM197 Mutant on Potassium-Doped Hydroxyapatite Microparticles. <i>Vaccine Journal</i> , <b>2015</b> , 22, 586-92		7
136	Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy. <i>Journal of Infection</i> , <b>2015</b> , 71, 43-52	18.9	57
135	A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. <i>Journal of Infection</i> , <b>2015</b> , 71, 326-37	18.9	29

134	Childhood meningitis in the conjugate vaccine era: a prospective cohort study. <i>Archives of Disease in Childhood</i> , <b>2015</b> , 100, 292-4	2.2	28
133	Identification of antigen-specific B cell receptor sequences using public repertoire analysis. <i>Journal of Immunology</i> , <b>2015</b> , 194, 252-261	5.3	90
132	The use of systems biology and immunological big data to guide vaccine development. <i>Genome Medicine</i> , <b>2015</b> , 7, 114	14.4	9
131	In-Depth Assessment of Within-Individual and Inter-Individual Variation in the B Cell Receptor Repertoire. <i>Frontiers in Immunology</i> , <b>2015</b> , 6, 531	8.4	60
130	Oral Wild-Type Salmonella Typhi Challenge Induces Activation of Circulating Monocytes and Dendritic Cells in Individuals Who Develop Typhoid Disease. <i>PLoS Neglected Tropical Diseases</i> , <b>2015</b> , 9, e0003837	4.8	13
129	An OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and Toxicity. <i>PLoS ONE</i> , <b>2015</b> , 10, e0134353	3.7	8
128	Effect of disorder on Raman scattering of single-layer MoS <sub>2</sub> . <i>Physical Review B</i> , <b>2015</b> , 91,	3.3	380
127	Analysis of B Cell Repertoire Dynamics Following Hepatitis B Vaccination in Humans, and Enrichment of Vaccine-specific Antibody Sequences. <i>EBioMedicine</i> , <b>2015</b> , 2, 2070-9	8.8	61
126	The capsular group B meningococcal vaccine, 4CMenB : clinical experience and potential efficacy. <i>Expert Opinion on Biological Therapy</i> , <b>2015</b> , 15, 131-42	5.4	14
125	Nucleation control for large, single crystalline domains of monolayer hexagonal boron nitride via Si-doped Fe catalysts. <i>Nano Letters</i> , <b>2015</b> , 15, 1867-75	11.5	121
124	Rapidly Escalating Hepcidin and Associated Serum Iron Starvation Are Features of the Acute Response to Typhoid Infection in Humans. <i>PLoS Neglected Tropical Diseases</i> , <b>2015</b> , 9, e0004029	4.8	25
123	Neuronal Antibodies in Children with or without Narcolepsy following H1N1-AS03 Vaccination. <i>PLoS ONE</i> , <b>2015</b> , 10, e0129555	3.7	16
122	High-resolution electrochemical and topographical imaging using batch-fabricated cantilever probes. <i>Analytical Chemistry</i> , <b>2014</b> , 86, 5143-9	7.8	35
121	Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. <i>Lancet, The</i> , <b>2014</b> , 384, 2123-31	4.0	212
120	Advancing the management and control of typhoid fever: a review of the historical role of human challenge studies. <i>Journal of Infection</i> , <b>2014</b> , 68, 405-18	18.9	30
119	Hospital admission rates for meningitis and septicaemia caused by Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae in children in England over five decades: a population-based observational study. <i>Lancet Infectious Diseases, The</i> , <b>2014</b> , 14, 397-405	25.5	81
118	Studying the antibody repertoire after vaccination: practical applications. <i>Trends in Immunology</i> , <b>2014</b> , 35, 319-31	14.4	77
117	Adjuvant effects elicited by novel oligosaccharide variants of detoxified meningococcal lipopolysaccharides on Neisseria meningitidis recombinant PorA protein: a comparison in mice. <i>PLoS ONE</i> , <b>2014</b> , 9, e115713	3.7	2

116	Quantitative characterization of defect size in graphene using Raman spectroscopy. <i>Applied Physics Letters</i> , <b>2014</b> , 105, 253107	3.4	46
115	Association between population prevalence of smoking and incidence of meningococcal disease in Norway, Sweden, Denmark and the Netherlands between 1975 and 2009: a population-based time series analysis. <i>BMJ Open</i> , <b>2014</b> , 4, e003312	3	11
114	An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 58, 1230-40	11.6	96
113	The serodominant secreted effector protein of Salmonella, SseB, is a strong CD4 antigen containing an immunodominant epitope presented by diverse HLA class II alleles. <i>Immunology</i> , <b>2014</b> , 143, 438-46	7.8	18
112	Polysaccharide-specific B cell responses to vaccination in humans. <i>Human Vaccines and Immunotherapeutics</i> , <b>2014</b> , 10, 1661-8	4.4	25
111	Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age. <i>Pediatric Infectious Disease Journal</i> , <b>2014</b> , 33, 760-6	3.4	32
110	Typhoid epidemiology, diagnostics and the human challenge model. <i>Current Opinion in Gastroenterology</i> , <b>2014</b> , 30, 7-17	3	34
109	The effect of chronic cytomegalovirus infection on pneumococcal vaccine responses. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 209, 1635-41	7	14
108	Group B meningococcal vaccine: recommendations for UK use. <i>Lancet, The</i> , <b>2014</b> , 383, 1103-4	40	20
107	The challenge of enteric fever. <i>Journal of Infection</i> , <b>2014</b> , 68 Suppl 1, S38-50	18.9	40
106	A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty. <i>Lancet Infectious Diseases, The</i> , <b>2014</b> , 14, 426-34	25.5	43
105	Pneumococcal serotype-specific antibodies persist through early childhood after infant immunization: follow-up from a randomized controlled trial. <i>PLoS ONE</i> , <b>2014</b> , 9, e91413	3.7	12
104	Evaluation of the induction of immune memory following infant immunisation with serogroup C Neisseria meningitidis conjugate vaccines--exploratory analyses within a randomised controlled trial. <i>PLoS ONE</i> , <b>2014</b> , 9, e101672	3.7	10
103	The B-cell response to a primary and booster course of MenACWY-CRM <sub>197</sub> vaccine administered at 2, 4 and 12 months of age. <i>Vaccine</i> , <b>2013</b> , 31, 2441-8	4.1	15
102	Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. <i>Vaccine</i> , <b>2013</b> , 31, 2852-61	4.1	79
101	Prevalence and genetic analysis of phenotypically Vi- negative Salmonella typhi isolates in children from Kathmandu, Nepal. <i>Journal of Tropical Pediatrics</i> , <b>2013</b> , 59, 317-20	1.2	9
100	Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. <i>Archives of Disease in Childhood</i> , <b>2013</b> , 98, 686-91	2.2	17
99	Prospects for prevention of Salmonella infection in children through vaccination. <i>Current Opinion in Infectious Diseases</i> , <b>2013</b> , 26, 254-62	5.4	21

98	Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease. <i>Archives of Disease in Childhood</i> , <b>2013</b> , 98, 248-51	2.2	16
97	Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. <i>Cmaj</i> , <b>2013</b> , 185, E715-24	3.5	57
96	Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis Serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom. <i>Pediatric Infectious Disease Journal</i> , <b>2013</b> , 32, 768-76	3.4	14
95	Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. <i>Pediatric Infectious Disease Journal</i> , <b>2013</b> , 32, 1116-21	3.4	34
94	Phase II study of a three-dose primary vaccination course of DTPa-IPV/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infants. <i>Pediatric Infectious Disease Journal</i> , <b>2013</b> , 32, 675-81	3.4	5
93	Assessment of T-dependent and T-independent immune responses in cattle using a B cell ELISPOT assay. <i>Veterinary Research</i> , <b>2012</b> , 43, 68	3.8	10
92	Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine. <i>Vaccine Journal</i> , <b>2012</b> , 19, 295-303		13
91	Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 307, 573-82	27.4	215
90	B cell memory to a serogroup C meningococcal conjugate vaccine in childhood and response to booster: little association with serum IgG antibody. <i>Journal of Immunology</i> , <b>2012</b> , 189, 2673-81	5.3	15
89	Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study. <i>Pediatric Infectious Disease Journal</i> , <b>2012</b> , 31, 1069-73	3.4	9
88	<i>Neisseria meningitidis</i> <b>2012</b> , 730-741.e7		1
87	Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy. <i>Expert Review of Vaccines</i> , <b>2011</b> , 10, 673-84	5.2	43
86	Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C <i>Neisseria meningitidis</i> given to adolescents previously immunized with a glycoconjugate vaccine. <i>Pediatric Infectious Disease Journal</i> , <b>2011</b> , 30, e203-8	3.4	10
85	Persistence of immunity following a booster dose of <i>Haemophilus influenzae</i> type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial. <i>Pediatric Infectious Disease Journal</i> , <b>2011</b> , 30, 197-202	3.4	27
84	Antibody repertoire: embracing diversity. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 93ps32	17.5	6
83	Multifunctional nanoprobe for nanoscale chemical imaging and localized chemical delivery at surfaces and interfaces. <i>Angewandte Chemie - International Edition</i> , <b>2011</b> , 50, 9638-42	16.4	218
82	Expert Review of Vaccines 10-year anniversary issue. <i>Expert Review of Vaccines</i> , <b>2011</b> , 10, 1489-1491	5.2	
81	Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 51, 1127-37	11.6	217



80	The epidemiology of meningococcal disease and the impact of vaccines. <i>Expert Review of Vaccines</i> , <b>2010</b> , 9, 285-98	5.2	100
79	Serogroup B meningococcal vaccines-an unfinished story. <i>Lancet Infectious Diseases</i> , <b>2010</b> , 10, 112-24	5.5	96
78	Comparison of a limiting dilution assay and ELISpot for detection of memory B-cells before and after immunisation with a protein-polysaccharide conjugate vaccine in children. <i>Journal of Immunological Methods</i> , <b>2010</b> , 358, 46-55	2.5	9
77	Challenges in immunisation against bacterial infection in children. <i>Early Human Development</i> , <b>2010</b> , 86, 695-701	2.2	9
76	Supramolecular assemblies formed on an epitaxial graphene superstructure. <i>Angewandte Chemie - International Edition</i> , <b>2010</b> , 49, 1794-9	16.4	104
75	Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. <i>Pediatric Infectious Disease Journal</i> , <b>2010</b> , 29, e71-9	3.4	137
74	Challenges and progress in the development of a serogroup B meningococcal vaccine. <i>Expert Review of Vaccines</i> , <b>2009</b> , 8, 729-45	5.2	20
73	Long-term immunological follow-up of children with haemophilus influenzae serotype b vaccine failure in the United Kingdom. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 49, 372-80	11.6	21
72	Kinetics of the natural, humoral immune response to Salmonella enterica serovar Typhi in Kathmandu, Nepal. <i>Vaccine Journal</i> , <b>2009</b> , 16, 1413-9		46
71	How does graphene grow? Easy access to well-ordered graphene films. <i>Small</i> , <b>2009</b> , 5, 2291-6	11	39
70	Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine. <i>Immunology</i> , <b>2009</b> , 127, 134-43	7.8	33
69	Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. <i>Nature Reviews Immunology</i> , <b>2009</b> , 9, 213-20	36.5	304
68	Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans. <i>Blood</i> , <b>2009</b> , 114, 4998-5002	2.2	89
67	Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2008</b> , 299, 173-84	27.4	175
66	Sustaining immunity after immunization against encapsulated bacteria. <i>Hum Vaccin</i> , <b>2008</b> , 4, 309-12		11
65	The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. <i>Journal of Immunology</i> , <b>2008</b> , 180, 2165-73	5.3	96
64	Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 46, 186-92	11.6	64
63	Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine. <i>Vaccine Journal</i> , <b>2008</b> , 15, 182-93		45

62	Vaccines for the Prevention of Admission to the Pediatric Intensive Care Unit <b>2008</b> , 143-175		
61	<i>Neisseria meningitidis</i> <b>2008</b> , 734-743		1
60	The role familiarity with science and medicine plays in parents' decision making about enrolling a child in vaccine research. <i>Qualitative Health Research</i> , <b>2007</b> , 17, 311-22	3.9	29
59	Social mixing with other children during infancy enhances antibody response to a pneumococcal conjugate vaccine in early childhood. <i>Vaccine Journal</i> , <b>2007</b> , 14, 593-9		20
58	Emergency management of meningococcal disease: eight years on. <i>Archives of Disease in Childhood</i> , <b>2007</b> , 92, 283-6	2.2	39
57	New combination vaccines still need a boost. <i>Archives of Disease in Childhood</i> , <b>2007</b> , 92, 1-2	2.2	5
56	Childhood immunisation: what is the future?. <i>Archives of Disease in Childhood</i> , <b>2007</b> , 92, 426-33	2.2	17
55	Reconsideration of the use of meningococcal polysaccharide vaccine. <i>Pediatric Infectious Disease Journal</i> , <b>2007</b> , 26, 716-22	3.4	70
54	A new combination haemophilus influenzae type B and <i>Neisseria meningitidis</i> serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants. <i>Pediatric Infectious Disease Journal</i> , <b>2007</b> , 26, 1057-9	3.4	32
53	Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. <i>Vaccine</i> , <b>2007</b> , 25, 264-71	4.1	41
52	Effectiveness analyses may underestimate protection of infants after group C meningococcal immunization. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 194, 231-7	7	15
51	Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial. <i>BMJ, The</i> , <b>2006</b> , 333, 571	5.9	54
50	Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 43, 1387-94	11.6	69
49	Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135. <i>Expert Review of Vaccines</i> , <b>2006</b> , 5, 445-59	5.2	11
48	CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. <i>Blood</i> , <b>2006</b> , 108, 2642-7	2.2	88
47	Course of Disease and Clinical Management <b>2006</b> , 481-517		1
46	The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine. <i>Immunology</i> , <b>2006</b> , 119, 328-37	7.8	43
45	Meningococcal polysaccharide-protein conjugate vaccines. <i>Lancet Infectious Diseases, The</i> , <b>2005</b> , 5, 21-30	5.5	147

44	Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. <i>Pediatric Infectious Disease Journal</i> , <b>2005</b> , 24, 128-31	3.4	85
43	Immunogenicity and immunologic memory of meningococcal C conjugate vaccine in premature infants. <i>Pediatric Infectious Disease Journal</i> , <b>2005</b> , 24, 966-8	3.4	22
42	Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 293, 1751-8	27.4	56
41	Rapid and fatal meningococcal disease due to a strain of <i>Neisseria meningitidis</i> containing the capsule null locus. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 40, e38-42	11.6	55
40	Immunological memory: the role of B cells in long-term protection against invasive bacterial pathogens. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 294, 3019-23	27.4	80
39	Global Epidemiology of Meningococcal Disease and Vaccine Efficacy. <i>Pediatric Infectious Disease Journal</i> , <b>2004</b> , 23, S274-S279	3.4	112
38	Disease susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America. <i>Emerging Infectious Diseases</i> , <b>2004</b> , 10, 1812-5	10.2	28
37	Eligibility of overseas visitors and people of uncertain residential status for NHS treatment. <i>BMJ, The</i> , <b>2004</b> , 329, 346-9	5.9	19
36	Differential post-transcriptional activation of human phagocytes by different <i>Pseudomonas aeruginosa</i> isolates. <i>Cellular Microbiology</i> , <b>2004</b> , 6, 639-50	3.9	10
35	Meningococcal vaccines. <i>Paediatric Drugs</i> , <b>2004</b> , 6, 251-66	4.2	15
34	Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children. <i>Vaccine</i> , <b>2004</b> , 22, 4262-9	4.1	33
33	Depressive pseudodementia in a child with autism. <i>Developmental Medicine and Child Neurology</i> , <b>2004</b> , 46, 485-9	3.3	2
32	Global epidemiology of meningococcal disease and vaccine efficacy. <i>Pediatric Infectious Disease Journal</i> , <b>2004</b> , 23, S274-9	3.4	92
31	Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years. <i>Pediatric Infectious Disease Journal</i> , <b>2003</b> , 22, 659-660	3.4	20
30	W135 in Africa: origins, problems and perspectives. <i>Travel Medicine and Infectious Disease</i> , <b>2003</b> , 1, 19-288.4		14
29	Epidemic meningococcal disease in sub-Saharan Africa--towards a sustainable solution?. <i>Lancet Infectious Diseases, The</i> , <b>2003</b> , 3, 68-70	25.5	12
28	Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years. <i>Pediatric Infectious Disease Journal</i> , <b>2003</b> , 22, 659-61	3.4	11
27	Meningococcal vaccines. <i>Expert Review of Vaccines</i> , <b>2002</b> , 1, 75-84	5.2	13

26	The meningococcus tamed?. <i>Archives of Disease in Childhood</i> , <b>2002</b> , 87, 13-7	2.2	18
25	Evaluation of a diagnostic polymerase chain reaction assay for <i>Neisseria meningitidis</i> in North America and field experience during an outbreak. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2002</b> , 126, 1209-15	5	20
24	Vaccine prevention of meningococcal disease, coming soon?. <i>Vaccine</i> , <b>2001</b> , 20, 666-87	4.1	81
23	Nonopsonic phagocytosis of <i>Pseudomonas aeruginosa</i> : insights from an infant with leukocyte adhesion deficiency. <i>Pediatric Infectious Disease Journal</i> , <b>2001</b> , 20, 452-4	3.4	12
22	Emerging infectious diseases in the 21st century. <i>Current Opinion in Infectious Diseases</i> , <b>2000</b> , 13, 265-275	5.4	9
21	Vaccines for prevention of meningococcal disease. <i>Pediatric Infectious Disease Journal</i> , <b>2000</b> , 19, 333-44; quiz 345	3.4	68
20	Assessment of immune response to meningococcal disease: comparison of a whole-blood assay and the serum bactericidal assay. <i>Microbial Pathogenesis</i> , <b>1999</b> , 27, 207-14	3.8	33
19	Humoral immune responses to <i>Neisseria meningitidis</i> in children. <i>Infection and Immunity</i> , <b>1999</b> , 67, 2441-51	5.1	31
18	Factors influencing participation in controlled human infection models: a pooled analysis from six enteric fever studies. <i>Wellcome Open Research</i> , <b>2014</b> , 4, 153	4.8	4
17	Electronic data capture for large scale typhoid surveillance, household contact tracing, and health utilisation survey: Strategic Typhoid Alliance across Africa and Asia		2
16	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses		7
15	Laboratory and Molecular Surveillance of Paediatric Typhoidal Salmonella in Nepal: Antimicrobial Resistance and Implications for Vaccine Policy		1
14	Targeted metagenomic sequencing enhances the identification of pathogens associated with acute infection		7
13	Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2		14
12	ChAdOx1 nCoV-19 (AZD1222) Vaccine in People Living With and Without HIV		3
11	Two doses of SARS-CoV-2 vaccination induce more robust immune responses to emerging SARS-CoV-2 variants of concern than does natural infection.		7
10	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity		4
9	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection		65

8	Divergent trajectories of antiviral memory after SARS-Cov-2 infection		4
7	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil; an exploratory analysis of a randomised controlled trial		3
6	Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7). <i>SSRN Electronic Journal</i> ,	1	28
5	Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine. <i>SSRN Electronic Journal</i> ,	1	2
4	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. <i>SSRN Electronic Journal</i> ,	1	2
3	Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern.		27
2	Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa		25
1	Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum		3